Target intelligence / Profile preview

Mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) pathway components (MEK/ERK pathway (component abbreviations include MEK, ERK))

Target
MEK/ERK pathway (component abbreviations include MEK, ERK)
Molecular classification
Enzyme (kinases: MEK, ERK), Signal transduction pathway components, Other (for pathway-level entries)
01

Overview

Mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinases (ERK) are core enzymes in the highly conserved MAPK/ERK signaling pathway. This pathway transduces signals from cell-surface receptors such as receptor tyrosine kinases to the nucleus, orchestrating critical cellular programs including proliferation, differentiation, and survival. The core architecture involves activation of RAS (a small GTPase), which thereby activates the RAF kinase, leading to phosphorylation and activation of MEK1/2 (MAP2K1/2), which then phosphorylate ERK1/2 (MAPK3/1). Activated ERK enters the nucleus to phosphorylate a wide array of transcription factors. Deregulation of this cascade is well established in various cancers, particularly through mutations in upstream components like RAS and BRAF, making the pathway a principal focus for targeted cancer therapies. Approved drugs primarily target MEK and to a lesser extent ERK, but resistance remains a clinical challenge due to redundancy and feedback within the broader network of cellular signaling pathways[1][4][5][6][7][8].\n\nPlease note that while \"Mitogen activated protein kinase kinase/extracellular signal-regulated kinases pathway components\" refers collectively to critical signaling molecules, for unambiguous scientific or clinical contexts it is essential to specify individual kinases (e.g., MEK1, ERK2) or refer to the \"MAPK/ERK signaling pathway\" as a general mechanism, but not as a discrete single-molecule drug target[7][3][4].

Other names
MEK/ERK pathwayMAPK/ERK pathwayRAS-RAF-MEK-ERK pathwayMitogen-activated protein kinase pathwayMAPK cascade
02

Mechanism of action

Inhibition of kinase activity (ATP-competitive or allosteric inhibition of MEK or ERK)\nSuppression of downstream phosphorylation events and gene transcription\nIndirect tumor suppression by blocking proliferation or promoting apoptosis

03

Biological functions

Signal transductionCell proliferationCell differentiationCell survivalCell death/apoptosisCell cycle regulationResponse to extracellular stimuli
04

Disease associations

Cancer (especially melanoma, lung, and colorectal tumors)InflammationCardiovascular diseaseNeurodegenerative disease (limited evidence)Drug resistance (in oncology)
05

Safety considerations

On-target toxicity in normal tissues (skin rash, cardiac toxicity)Resistance via pathway reactivation or compensatory signaling (e.g., PI3K/AKT pathway)Limited efficacy in tumors with KRAS mutations not directly targetableSecondary malignancies (rare but noted with some inhibitors)
06

Interacting drugs

MEK inhibitors: trametinib, cobimetinib, binimetinib, selumetinib

3 more in the full profile.

07

Biomarkers

Phosphorylated ERK (p-ERK, activation marker)Mutations in KRAS, BRAF, NRAS (predictive of pathway activation and therapy response)Phosphorylated MEKGene expression profiles of downstream effectors

Beyond the preview

Go deeper on Mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) pathway components (MEK/ERK pathway (component abbreviations include MEK, ERK)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) pathway components (MEK/ERK pathway (component abbreviations include MEK, ERK)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call